MacuLogix, a company focused on the detection and following of age-related macular degeneration, has announced that the company has received $3.6 million in Series A funding for its AdaptDx.
AdaptDx is designed to be an easy to use macular degeneration diagnostic tool.
Investors contributing to MacuLogix's Series A funding include Ben Franklin Technology Partners of Central and Northern Pennsylvania, Berwind Private Equity, Roche Venture Fund and Life Sciences Greenhouse of Central Pennsylvania.
More Articles on Ophthalmology:
Flaum Eye Institute Recruits Dr. Harold Ross
MCRHS Eye Care Welcomes Dr. Elizabeth Garland
AAO Survey Finds US Ophthalmologists Foresee Negative Consequences of Medicare Cuts
AdaptDx is designed to be an easy to use macular degeneration diagnostic tool.
Investors contributing to MacuLogix's Series A funding include Ben Franklin Technology Partners of Central and Northern Pennsylvania, Berwind Private Equity, Roche Venture Fund and Life Sciences Greenhouse of Central Pennsylvania.
More Articles on Ophthalmology:
Flaum Eye Institute Recruits Dr. Harold Ross
MCRHS Eye Care Welcomes Dr. Elizabeth Garland
AAO Survey Finds US Ophthalmologists Foresee Negative Consequences of Medicare Cuts